The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth

doi:10.21037/atm.2019.12.86

Editorial

. 2019 Dec;7(Suppl 8):S388.

doi: 10.21037/atm.2019.12.86.

The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth

Joseph D Frasca¹, Adam S Cheifetz²

Affiliations

¹ Univeristy of Vermont Medical Center, Burlington, VT, USA.
² Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA.

PMID: 32016106
PMCID: PMC6976392
DOI: 10.21037/atm.2019.12.86

Editorial

The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth

Joseph D Frasca et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S388.

doi: 10.21037/atm.2019.12.86.

Authors

Joseph D Frasca¹, Adam S Cheifetz²

Affiliations

¹ Univeristy of Vermont Medical Center, Burlington, VT, USA.
² Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA.

PMID: 32016106
PMCID: PMC6976392
DOI: 10.21037/atm.2019.12.86

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: AS Cheifetz: Consulting: Janssen, Abbvie, Takeda, Pfizer, Samsung, Arena, Bacainn, EMD Serono, Arsanis, Grifols, Prometheus; Research support: Inform Diagnostics. The other author has no conflicts of interest to declare.

Comment on

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
Murthy SK, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, Singh H, Targownik L, Taljaard M. Murthy SK, et al. Gut. 2020 Feb;69(2):274-282. doi: 10.1136/gutjnl-2019-318440. Epub 2019 Jun 12. Gut. 2020. PMID: 31196874 Free PMC article.

References

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 Study Group. N Engl J Med 1997;337:1029-35. 10.1056/NEJM199710093371502 - DOI - PubMed
1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. 10.1016/S0140-6736(02)08512-4 - DOI - PubMed
1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. 10.1056/NEJMoa050516 - DOI - PubMed
1. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876-85. 10.1056/NEJMoa030815 - DOI - PubMed
1. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.e1-3. 10.1053/j.gastro.2011.10.032 - DOI - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 Study Group. N Engl J Med 1997;337:1029-35. 10.1056/NEJM199710093371502 - DOI - PubMed

[2] Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 Study Group. N Engl J Med 1997;337:1029-35. 10.1056/NEJM199710093371502 - DOI - PubMed

[3] Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. 10.1016/S0140-6736(02)08512-4 - DOI - PubMed

[4] Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. 10.1016/S0140-6736(02)08512-4 - DOI - PubMed

[5] Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. 10.1056/NEJMoa050516 - DOI - PubMed

[6] Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. 10.1056/NEJMoa050516 - DOI - PubMed

[7] Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876-85. 10.1056/NEJMoa030815 - DOI - PubMed

[8] Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876-85. 10.1056/NEJMoa030815 - DOI - PubMed

[9] Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.e1-3. 10.1053/j.gastro.2011.10.032 - DOI - PubMed

[10] Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.e1-3. 10.1053/j.gastro.2011.10.032 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth

Affiliations

The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources